Holmium laser enucleation for large (greater than 100 mL) prostate glands.
BACKGROUND
To evaluate the holmium laser enucleation of the prostate (HoLEP) using the transurethral soft tissue morcellator (TUSTM), as a primary surgical treatment for symptomatic benign prostatic hyperplasia (BPH) with prostate glands > 100 mL.


METHODS
Eighteen patients with preoperative prostate volumes > 100 mL underwent the HoLEP procedure. The criteria for surgery were determined by a preoperative International Prostate Symptom Score (IPSS), a prior failure of medical therapy, and urinary retention.


RESULTS
The mean preoperative IPSS and prostate gland size were 13.8 and 142.3 mL, respectively. The total energy used by the laser was 288.4 kJ. The mean catheter time was 23.8 h and, perioperatively, no patients had electrolyte abnormalities or required blood transfusions. The 3-week postoperative IPSS was 2.8, with minimum long-term complications.


CONCLUSIONS
Holmium laser enucleation of the prostate with TUSTM is a safe and effective alternative to open prostatic surgery for glands > 100 mL.
Hettiarachchi
Janaka A
JA
Department of Urology, New York Medical College, Valhalla 10595, USA.
Samadi
Albert A
AA
Konno
Sensuke
S
Das
Akhil K
AK
D000368:Aged; D005500:Follow-Up Studies; D006695:Holmium; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D011470:Prostatic Hyperplasia / Q000601:surgery*; D016896:Treatment Outcome
D006695:Holmium